Our innovative research receives support from public and private funding sources that recognize the high-value impact of our work.
Zackary Falls, PhD
A translational bioinformatics approach to elucidate and mitigate polypharmacy induced adverse drug reactions. Zackary Falls (Principal Investigator). National Institute on Drug Abuse. $1,046,435. 7/1/2022-6/1/2027.
Buffalo Research Innovation in Genomic and Healthcare Technology (BRIGHT) Short-Term Training and Education. Zackary Falls (Co-Investigator). National Library of Medicine. $667,598. 9/1/2022-8/1/2027.
High-performance Computing Drug Discovery Initiative. Zackary Falls (Co-Investigator). National Institute of Standards and Technology (NIST). $1,000,000. 11/1/2022-10/1/2023.
Buffalo Clinical and Translational Research Center Clinical and Translational Science Award (CTSA). Ram Samudrala (Co-Investigator). National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health. $20,178,410. 12/1/2019-12/1/2024.
Computational Analysis of Novel Drug Opportunities (CANDO). Ram Samudrala (Principal Investigator). Buffalo Innovation Accelerator Fund. $80,000. 2/1/2021-12/1/2022.
Buffalo Research Innovation in Genomic and Healthcare Technology (BRIGHT) Short-Term Training and Education. Ram Samudrala (Principal Investigator). NIH. $672,596. 9/1/2022-8/1/2027.
High performance computing drug discovery initiative. Ram Samudrala (Principal Investigator). NIST. $1,000,000. 11/1/2022-10/1/2023.
Buffalo Research Innovation in Genomic and Healthcare Technology (BRIGHT) Training and Education. Ram Samudrala (Co-Investigator). NIH/NLM. $4,546,884. 7/1/2017-6/1/2027.
Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, Falls Z, Samudrala R, Pohl J, Knight PR, Sambhara S. (2023) Antiviral Approaches against Influenza Virus. Clinical microbiology reviews (Jan)e0004022.
Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, Falls Z, Samudrala R, Pohl J, Knight PR, Sambhara S. (2023) Antiviral Approaches against Influenza Virus. Clinical microbiology reviews (Jan)e0004022.